Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories




 

Medicines For Ireland Appoints New Chairs Following Framework Agreement

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Executive Changes Ireland

Coronavirus Spotlight

Coronavirus Spotlight

Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

Biosimilars Coronavirus COVID-19

Interviews

Interviews

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars

With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Biosimilars Strategy

Generics Bulletin Editor’s Picks For Q4 2021

As 2021 drew to a close, there was no shortage of exciting developments for the off-patent industry. Alongside news of a strategic review affecting one of the biggest generics and biosimilars players, Generics Bulletin also held its annual Global Generics & Biosimilars Awards and brought readers fresh and exclusive insights from top industry executives.

Generic Drugs Biosimilars Strategy
 

Commercial Explore this Topic

Set Alert for Commercial

Medicines For Ireland Appoints New Chairs Following Framework Agreement

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Executive Changes Ireland

Biocon Finalizes Merger Between Covidshield And Biologics Business

The merger between Serum Institute of India subsidiary Covidshield Technologies and Biocon Biologics has finally completed, subject to requisite approvals, after a Biocon board meeting.

M & A Deals

IGBA Appoints Frittelli As 2022 Chair

The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.

Executive Changes Generic Drugs

Amgen Provides Ambitious Update On Biosimilars Business

Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.

Biosimilars Launches

Hikma Buys Teligent Assets To Expand Into Canada

Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.

Deals Canada

American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch

With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.

Generic Drugs Value-Added Medicines
See All

Policy & Regulation Explore this Topic

Set Alert for Policy and Regulation

Teva Comments On Sandoz Implications Amid Strategic Review

Teva CEO Kåre Schultz has weighed in on Novartis’ plans to conduct a strategic review for its Sandoz unit, while also airing frustrations over continued delays for complex products in the US.

Market Intelligence Commercial

Biocon And Viatris Get CRL From FDA On Insulin Aspart

Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.

Biosimilars United States

Is CREATES Act Equipped To Handle Biosimilar Complaints?

Biosimilar sponsors need multiple reference product lots and expiration dates, and questions remain about whether they can obtain enough to fulfill all regulatory requirements under a CREATES Act mandate, Teva attorney says.

Biosimilars Legal Issues

Eagle Bags Vasopressin Exclusivity And Details Launch Plans

Generic competition to Vasostrict is nearing in the US after the FDA confirmed Eagle’s previously unresolved potential for 180-day market exclusivity.

Regulation FDA

Wave Of Molnupiravir Generics In India Amid Early Physician Cheer

India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of  Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.

Approvals Coronavirus COVID-19

Teva Plans Action After Losing Opioids Trial In New York

Following a mammoth six-month trial, a jury in New York has issued a verdict finding that Teva and some of its affiliates are liable for the public nuisance charges made by New York state in its opioid trial in Suffolk County State Supreme Court.

Advertising, Marketing & Sales Legal Issues
See All

Generic Drugs Explore this Topic

Set Alert for Generic Drugs

Medicines For Ireland Appoints New Chairs Following Framework Agreement

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Executive Changes Ireland

Multiple Molecules See UK Prices More Than Double In December

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Market Intelligence Pricing Strategies

IGBA Appoints Frittelli As 2022 Chair

The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.

Executive Changes Generic Drugs
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

Medicines For Ireland Appoints New Chairs Following Framework Agreement

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Executive Changes Ireland

IGBA Appoints Frittelli As 2022 Chair

The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.

Executive Changes Generic Drugs

Amgen Provides Ambitious Update On Biosimilars Business

Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.

Biosimilars Launches
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch

With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.

Generic Drugs Value-Added Medicines

Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

Approvals Value-Added Medicines

What’s Next? Five Things To Look Out For In January

Sun Pharma’s key antitrust trial kicks off and Lannett awaits word from the US FDA for its generic Advair filing during a busy first month of 2022, which also features updates from the annual J.P. Morgan Health Care Conference.

Biosimilars Generic Drugs
See All
UsernamePublicRestriction

Register